Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + 5FU-Based Therapy in First-Line Advanced Colorectal Cancer
NCT07042685Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (CRC), sponsored by Houston Methodist Research Institute. Started Jan 2026; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07042685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042685.